Board Meeting On 30.05.2017
Board meeting on 30.05.2017 for consideration of audited financial results for the quarter and year ended 31.03.201719-05-2017
19-05-2017
Shareholding for the Period Ended March 31, 2017
Ortin Laboratories Ltd has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2017. For more details, kindly Click here19-04-2017
Statement On Investor Complaints As On 31.03.2017
Statement on Investor Complaints as on 31.03.201719-04-2017
Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for A Prabhakar Raju16-03-2017
Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for A Srinivasa Raju10-03-2017
Outcome of Board Meeting
Ortin Laboratories Ltd has informed BSE that the Board of Directors of the Company at its meeting held on February 14, 2017, inter alia, has reviewed the status of demerger process requesting the independent Auditors and Merchant Bankers to expedite the completion of the reports and submit the same to the Company.16-02-2017
Standalone Financial Results, Limited Review Report for December 31, 2016
Ortin Laboratories Ltd has informed BSE about : 1. Standalone Financial Results for the period ended December 31, 20162. Standalone Limited Review for the period ended December 31, 201614-02-2017
Updates on ensuing Board Meeting on Feb 14, 2017
With reference to the earlier letter dated January 30, 2017, Ortin Laboratories Ltd has now informed BSE that the Board of Directors of the Company in their scheduled Meeting on February 14, 2017, will also consider on the progress of demerger process including valuation report, fairness opinion etc., apart from considering unaudited financial results for the quarter ended December 31, 2016.06-02-2017